A Phase Ii, Open-Label, Randomized Study To Evaluate The Efficacy And Safety Of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone In Subjects With Unresectable Or Recurrent Gastric Or Gastroesophageal Junction Adenocarcinoma.
JOURNAL OF CLINICAL ONCOLOGY（2019）
摘要
75Background: Andecaliximab (ADX) is a monoclonal antibody that inhibits matrix metalloproteinase 9 (MMP9). Preclinical studies suggest that MMP9 inhibition relieves immune suppression and promotes...
更多查看译文
关键词
Nivolumab,Gastroesophageal Junction Adenocarcinoma,Monoclonal antibody,Immune system,MMP9,Oncology,Randomized controlled trial,Pathology,Medicine,Internal medicine,Matrix metalloproteinase 9,Open label
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要